Andere Kunden interessierten sich auch für
![Expression of Adiponectin Receptors in Non-small Cell Lung Carcinoma]( "Expression of Adiponectin Receptors in Non-small Cell Lung Carcinoma")
Expression of Adiponectin Receptors in Non-small Cell Lung Carcinoma26,99 €![Introduction to Small and Non- Small Lung Cancer Patients]( "Introduction to Small and Non- Small Lung Cancer Patients")
Introduction to Small and Non- Small Lung Cancer Patients46,99 €![Molecular Mechanisms of Non-Small Cell Lung Cancer]( "Molecular Mechanisms of Non-Small Cell Lung Cancer")
Molecular Mechanisms of Non-Small Cell Lung Cancer39,99 €![Obstetric and Neonatal Care in Small Island States]( "Obstetric and Neonatal Care in Small Island States")
Obstetric and Neonatal Care in Small Island States40,99 €![PALLADIUM,RUTHENIUM AND RHODIUM COMPLEXES AS CHEMOTHERAUPETIC AGENTS]( "PALLADIUM,RUTHENIUM AND RHODIUM COMPLEXES AS CHEMOTHERAUPETIC AGENTS")
PALLADIUM,RUTHENIUM AND RHODIUM COMPLEXES AS CHEMOTHERAUPETIC AGENTS51,99 €![Comparative study of TURP in small & large size prostate in BHP]( "Comparative study of TURP in small & large size prostate in BHP")
Comparative study of TURP in small & large size prostate in BHP26,99 €![Small scale farmers perceptions on pesticides usage and practices]( "Small scale farmers perceptions on pesticides usage and practices")
Small scale farmers perceptions on pesticides usage and practices26,99 €
Background: Previous studies have reported on the patterns of use of first-line chemotherapy with platinum doublets in advanced NSCLC. There are no studies of patterns of use of newer agents in advanced NSCLC. We evaluated the nationwide incidence and predictors of use of new agents including bevacizumab, erlotinib, and pemetrexed. Methods: We retrospectively selected patients with stage IIIB/IV NSCLC diagnosed in 2005 from a random sample drawn from SEER registries to abstract data on clinical and socio-demographic factors and types of anti-cancer drug regimens for up to two years from diagnosis. We used descriptive statistics to report the incidence of use of bevacizumab, erlotinib, and pemetrexed. We used multiple logistic regression to detect predictors of treatment with these new agents.